Evaxion Biotech A/S (EVAX)
NASDAQ: EVAX
· Real-Time Price · USD
2.11
-0.29 (-12.08%)
At close: Jun 17, 2025, 3:59 PM
2.08
-1.32%
After-hours: Jun 17, 2025, 07:43 PM EDT
-12.08% (1D)
| Bid | 2.07 |
| Market Cap | 2.96M |
| Revenue (ttm) | 3.35M |
| Net Income (ttm) | -10.57M |
| EPS (ttm) | -12 |
| PE Ratio (ttm) | -0.18 |
| Forward PE | -1.96 |
| Analyst | Buy |
| Ask | 2.09 |
| Volume | 128,553 |
| Avg. Volume (20D) | 92,250 |
| Open | 2.42 |
| Previous Close | 2.40 |
| Day's Range | 2.07 - 2.47 |
| 52-Week Range | 1.20 - 17.75 |
| Beta | 0.10 |
About EVAX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol EVAX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for EVAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+25.53%
Evaxion shares are trading higher after the compan...
Unlock content with
Pro Subscription
4 months ago
-8.56%
Evaxion Biotech shares are trading lower. The stock may be moving on continued weakness after Lake Street cut its price target on the stock yesterday from $35 to $6.
3 weeks ago · seekingalpha.com
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call TranscriptEvaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call May 27, 2025 8:30 PM ET Company Participants Christian Kanstrup - CEO Birgitte Rono - Chief Scientific Officer Thomas Schmidt - CFO Conferen...
3 weeks ago · seekingalpha.com
Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily ...
